Taral Patel MD

Physician

Summary

Dr. Taral Patel is an oncologist based in Columbus, OH, with extensive training in hematology and medical oncology from the University of Cincinnati Medical Center/College of Medicine. He completed his residency in internal medicine at Cook County Health and Hospitals System. He is affiliated with several medical centers in Ohio, including OhioHealth Grant Medical Center and OhioHealth Grady Memorial Hospital, and practices at Mid-Ohio Oncology/Hematology, Inc. His clinical expertise covers gallbladder cancer, amyloidosis, cancer-associated retinopathy, hematologic oncology, and prostate cancer. Dr. Patel has contributed to published research in high-impact journals, notably in areas related to coronary interventions and oncology therapies. His work has garnered significant citations, particularly his study published in The New England Journal of Medicine. Furthermore, he holds CMS Meaningful Use certifications for medical oncology.

University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1998
Cook County Health and Hospitals SystemResidency, Internal Medicine, 1992 - 1995
Baroda Medical CollegeClass of 1989

CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2012, 2014, 2016-2017

PubMed

12 citations
Distal Radial Access in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS-CTO Registry.
Ilias Nikolakopoulos, Taral Patel, Brian K. Jefferson, Abdul M. Sheikh, Wissam Jaber
The Journal of Invasive Cardiology. 2021-08-19
48 citations
Procedural Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions Via the Radial Approach: Insights From an International Chronic Total Occlusion...
Peter Tajti, Khaldoon Alaswad, Dimitri Karmpaliotis, Farouc A. Jaffer, Robert W. Yeh
JACC. Cardiovascular Interventions. 2019-02-25
4 citations
Efficacy and Safety Results of the Afatinib Expanded Access Program
Edward S. Kim, Balazs Halmos, Ingrid F. Kohut, Taral Patel, Regan D. Rostorfer
Oncology and Therapy. 2017-04-10

Abstracts/Posters

Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who ar...
Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm J, Hecht J, Perrou B, Griffing S, Nelson B, Novotny W, ASCO, Multiple Locations, 1/1/2004
A Single Pegfilgrastim Dose Per Cycle Supports Dose-Dense (q14d) CHOP-R in Patients with NHL
Moore T, Patel T, Segal M, Zangmeister J, Chidiac T, Roach R, Thompson M, Larrimer N., Journal of American Society of Hematology – Blood, 11/16/2002
Second-Line Chemotherapy with Weekly Gemcitabine and Monthly Docetaxel in Patients with Metastatic Breast Cancer: A Phase II Study
Laufman LR, Spiridonidis CH, Carman L, Pritchard J, Roach R, Zangmeister J, Larrimer N, Jones J, Moore T, Segal M, Patel T, Gutterman L, Program/Proceedings of ASCO, Columbus, OH, 1/1/2000

Lectures

Superior Vena Cava Syndrome: An Oncological Emergency
1/1/1998
Polycythemia. Hematology Oncology Lecture Series
1/1/1998
Case presentation of Locally Advanced Pancreatic Cancer Treated with Gemcitabine
Denver, CO - 1/1/1997